Clinical effect of modified Guipi Decoction on language function of children with cblC methylmalonic aciduria

注册号:

Registration number:

ITMCTR2100004632

最近更新日期:

Date of Last Refreshed on:

2021-03-25

注册时间:

Date of Registration:

2021-03-25

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

加减归脾汤干预cblC型甲基丙二酸尿症患儿语言功能的临床疗效研究

Public title:

Clinical effect of modified Guipi Decoction on language function of children with cblC methylmalonic aciduria

注册题目简写:

English Acronym:

研究课题的正式科学名称:

归脾汤干预MMA言语障碍的临床疗效及机制研究

Scientific title:

Clinical efficacy and mechanism of Guipi Decoction in the treatment of MMA speech disorder

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100044682 ; ChiMCTR2100004632

申请注册联系人:

李甜馨

研究负责人:

张璠

Applicant:

Li Tian-Xin

Study leader:

Zhang Fan

申请注册联系人电话:

Applicant telephone:

+86 15638437330

研究负责人电话:

Study leader's telephone:

+86 15890180506

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

litianxinc@163.com

研究负责人电子邮件:

Study leader's E-mail:

zhangfan777777@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

河南省郑州市金水区东明路河南中医药大学东明校区

研究负责人通讯地址:

河南省郑州市金水区人民路19号

Applicant address:

Dongming Road, Jinshui District, Zhengzhou, Henan

Study leader's address:

19 Renmin Road, Jinshui District, Zhengzhou, Henan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河南中医药大学

Applicant's institution:

Henan University of traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020HL-116-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

河南中医药大学第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/11/12 0:00:00

伦理委员会联系人:

王春芳

Contact Name of the ethic committee:

Wang Chun-Fang

伦理委员会联系地址:

河南省郑州市金水区人民路19号

Contact Address of the ethic committee:

19 Renmin Road, Jinshui District, Zhengzhou, Henan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 371-66285929

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河南中医药大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Henan University of traditional Chinese Medicine

研究实施负责(组长)单位地址:

河南省郑州市金水区人民路19号

Primary sponsor's address:

19 Renmin Road, Jinshui District, Zhengzhou, Henan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

河南中医药大学第一附属医院

具体地址:

金水区人民路19号

Institution
hospital:

The First Affiliated Hospital of Henan University of traditional Chinese Medicine

Address:

19 Renmin Road, Jinshui District

经费或物资来源:

河南省中医药科学研究专项课题

Source(s) of funding:

Special project of scientific research on traditional Chinese medicine in Henan Province

研究疾病:

甲基丙二酸尿症

研究疾病代码:

Target disease:

Methylmalonic aciduria

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

通过评价加减归脾汤干预MMA患儿语言功能异常的有效性、安全性,为干预MMA语言功能异常提供新的辅助药物。

Objectives of Study:

Objective to evaluate the effectiveness and safety of Jiajian Guipi Decoction in the treatment of abnormal language function in children with MMA.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合心脾两虚证cblC型MMA诊断; (2)伴有语言功能异常的临床表现,语言功能异常的判定参考S-S语言发育迟缓检查法评估结果; (3)年龄在1~5岁龄; (4)患儿法定监护人签署知情同意书,并愿意接受中药治疗和临床调查。

Inclusion criteria

(1) It was consistent with the diagnosis of cblC type MMA of deficiency of both heart and spleen; (2) For the clinical manifestations with abnormal language function, the assessment results of S-S language retardation test were referred to for the determination of language dysfunction; (3) They were aged from 1 to 5 years old; (4) The legal guardian of the child signed the informed consent and was willing to accept traditional Chinese medicine treatment and clinical investigation.

排除标准:

(1)存在合并严重的视力障碍、听力障碍、心脑血管疾病者; (2)合并严重影响语言功能的其他疾病,如甲状腺功能减退症、脑积水者; (3)合并重症感染、肝肾功能异常及代谢紊乱者。

Exclusion criteria:

(1) There were severe visual impairment, hearing impairment, cardiovascular and cerebrovascular diseases; (2) Patients with other diseases that seriously affect language function, such as hypothyroidism and hydrocephalus; (3) Patients with severe infection, abnormal liver and kidney function and metabolic disorder.

研究实施时间:

Study execute time:

From 2021-03-24

To      2022-06-01

征募观察对象时间:

Recruiting time:

From 2021-03-24

To      2022-03-01

干预措施:

Interventions:

组别:

试验组

样本量:

36

Group:

Experimental group

Sample size:

干预措施:

加减归脾汤+西药常规治疗+言语训练

干预措施代码:

Intervention:

Modified Guipi Decoction + conventional western medicine treatment + speech training

Intervention code:

组别:

对照组

样本量:

36

Group:

Control group

Sample size:

干预措施:

安慰剂+西药常规治疗+言语训练

干预措施代码:

Intervention:

Placebo + routine western medicine treatment + speech training

Intervention code:

样本总量 Total sample size : 72

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河南

市(区县):

Country:

China

Province:

Henan

City:

单位(医院):

河南中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Henan University of traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

PedsQLTM 4.0普适性核心量表

指标类型:

次要指标

Outcome:

Pedsqltm 4.0 universal core scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

S-S语言发育迟缓检查法

指标类型:

主要指标

Outcome:

S-S language retardation test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 1
Min age years
最大 6
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

依纳入先后顺序将病例编号,由专人查随机数字表将其分成两组,单数代表A组,双数代表B组。符合纳入标准的患儿按纳入时间先后顺序随机分组,并依照分组情况进行对应药物的发放。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to the order of admission, the cases were numbered and divided into two groups according to the random number table. The singular number represents group A, and the even number represents group B.

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台 http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical Trial Management Public Platform http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

(1)试验前统一培训研究人员,熟练掌握试验实施流程及具体操作方法。 (2)试验过程中,由试验人员定期检查、考核研究情况。 (3)病例入选时评价及后期疗效评价,由专门评估人员评估,且保证每例患儿前后评估均由同一评估人员评估。 (4)临床观察表格的填写,按照具体规定要求,试验前进行详细说明和规定。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

(1) Before the experiment, researchers should be trained to master the experiment implementation process and specific operation methods. (2) During the test, the researchers regularly check and assess the research situation. (3) The evaluation at the time of case selection and the evaluation at the later stage were evaluated by special evaluators, and the evaluation before and after each case was evaluated by the same evaluator. (4) The clinical observation form shall be filled in according to the specific requirements, and detailed description and regulation shall be made before the test.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above